title: Immunization with pneumococcal polysaccharide serotype 3 and lipopolysaccharide modulates lung and liver inflammation during a virulent Streptococcus pneumoniae infection in mice.
abstract: Vaccination reduces morbidity and mortality from pneumonia, but its effect on the tissue-level response to infection is still poorly understood. We evaluated pneumonia disease progression, acute-phase response, and lung gene expression profiles in mice inoculated intranasally with virulent Gram-positive Streptococcus pneumoniae serotype 3 (ST 3) with and without prior immunization with pneumococcal polysaccharide ST 3 (PPS3) or after coimmunization with PPS3 and a low dose of lipopolysaccharide (PPS3+LPS). Pneumonia severity was assessed in the acute phase at 5, 12, 24 and 48 h postinoculation (p.i.) and in the resolution phase at 7 days p.i. Primary PPS3-specific antibody production was upregulated, and IgM binding to pneumococci increased in PPS3-immunized mice. Immunizations with PPS3 or PPS3+LPS decreased bacterial recovery in the lung and blood at 24 and 48 h and increased survival. Microarray analysis of whole-lung RNA revealed significant changes in the acute-phase protein serum amyloid A (SAA) levels between noninfected and infected mice, and these changes were attenuated by immunization. SAA transcripts were higher in the liver and lungs of infected controls, and SAA protein was elevated in serum but decreased in PPS3-immunized mice. Thus, during a virulent pneumonia infection, prior immunization with PPS3 in an IgM-dependent manner as well as immunization with PPS3+LPS attenuated pneumonia severity and promoted resolution of infection, concomitant with significant regulation of cytokine gene expression levels in the lungs and acute-phase proteins in the lungs, liver, and serum.
authors: Graduate Program in Immunology and Infectious Disease, The Huck Institute of Life Sciences, Pennsylvania State University, University Park, Pennsylvania, USA.
authors: Katherine H
authors: KH
authors: Restori
authors: Mary J
authors: MJ
authors: Kennett
authors: A Catharine
authors: AC
authors: Ross
mesh_terms: D000209:Acute-Phase Proteins / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D007075:Immunoglobulin M / Q000276:immunology; D007249:Inflammation / Q000628:therapy; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology*; D008099:Liver / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology*; D000685:Serum Amyloid A Protein / Q000096:biosynthesis / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
chemical_list: D000209:Acute-Phase Proteins; D000907:Antibodies, Bacterial; D016207:Cytokines; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D000685:Serum Amyloid A Protein; C026604:pneumococcal polysaccharide, type III
references: Infect Immun. 2009 Jan;77(1):464-71
references: 19001076
references: J Infect Dis. 1994 Feb;169(2):441-4
references: 8106780
references: PLoS Pathog. 2007 Sep 28;3(9):1208-19
references: 17845072
references: Nature. 2007 Jul 26;448(7152):501-5
references: 17618271
references: J Immunol. 2009 Apr 15;182(8):4931-7
references: 19342672
references: Eur J Biochem. 1999 Oct;265(2):501-23
references: 10504381
references: Cleve Clin J Med. 2012 Jan;79(1):67-78
references: 22219236
references: Infect Immun. 2005 Aug;73(8):4530-8
references: 16040964
references: Scand J Infect Dis. 2003;35(8):488-90
references: 14514149
references: Scand J Immunol. 1998 Oct;48(4):410-8
references: 9790312
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Cell Mol Life Sci. 2008 Oct;65(20):3231-40
references: 18668203
references: Wkly Epidemiol Rec. 2007 Mar 23;82(12):93-104
references: 17380597
references: Proc Natl Acad Sci U S A. 1980 Nov;77(11):6860-4
references: 6161374
references: Microb Pathog. 2009 Sep;47(3):157-63
references: 19467320
references: Clin Exp Immunol. 2003 Oct;134(1):23-31
references: 12974750
references: Respir Med. 2011 Dec;105(12):1776-83
references: 21816596
references: Scand J Clin Lab Invest. 2003;63(4):267-72
references: 12940634
references: Adv Carbohydr Chem. 1964;19:303-58
references: 14272331
references: PLoS One. 2012;7(7):e40778
references: 22815814
references: Cytokine. 2008 May;42(2):145-151
references: 18304834
references: Infect Immun. 2009 Jun;77(6):2417-26
references: 19289507
references: J Biol Chem. 1986 Jul 25;261(21):9644-51
references: 3525531
references: Biochem Biophys Res Commun. 2006 Sep 15;348(1):145-52
references: 16876127
references: Rev Infect Dis. 1981 Mar-Apr;3(2):332-41
references: 6973183
references: J Immunol. 2009 Nov 15;183(10):6186-97
references: 19864596
references: Science. 2007 Jun 15;316(5831):1628-32
references: 17569868